Correction of iron deficiency in the cardiorenal syndrome

Area of Science:

• Cardiology
• Nephrology
• Metabolic Disorders

Background:

• Impaired energy metabolism is a hallmark of Congestive Heart Failure (CHF).
• Iron deficiency is prevalent in both Chronic Kidney Disease (CKD) and CHF, impacting cellular energy production.
• Emerging evidence indicates iron deficiency as an independent mortality risk factor in CHF.

Purpose of the Study:

• To evaluate the impact of correcting iron deficiency with intravenous (IV) iron on patients with CKD and CHF.
• To determine if improvements in cardiac function, exercise capacity, and quality of life are linked to iron status, independent of anemia.

Main Methods:

• Review of studies investigating IV iron therapy in CKD and CHF patients.
• Analysis of outcomes including anemia correction, renal function, cardiac function, exercise capacity, and quality of life.

Main Results:

• IV iron administration improved anemia and, in some cases, renal function in both CKD and CHF cohorts.
• CHF patients receiving IV iron showed enhanced cardiac function, structure, exercise capacity, and quality of life.
• These improvements were observed even in patients without anemia, suggesting iron deficiency's independent detrimental effect.

Conclusions:

• Correction of iron deficiency with IV iron shows promise in managing cardiorenal syndrome.
• Iron deficiency may independently contribute to the progression of CHF and CKD.
• Routine assessment of iron deficiency parameters in CKD and CHF patients, irrespective of anemia, is warranted.